EMR logo

Emerson Electric

EMR · What the business does, what can go wrong, and how options sellers approach it

What it does

Emerson Electric makes automation technology for industrial customers. Its products include control systems, valves, measurement instruments and the software that runs them. Customers include chemical, oil and gas, power, life sciences and manufacturing companies.

The company has reshaped itself over time, selling off businesses outside automation (such as its former climate and consumer lines) to focus on this area.

How it makes money

Emerson sells equipment, software and related services to industrial operators. Revenue comes from:

  • Initial projects, such as outfitting a new plant or upgrading an old control system.
  • Ongoing work, including maintenance, replacement parts, software licenses and support.

Ongoing work tends to be steadier than big projects, which depend on customers' capital budgets.

Why investors own it

  • Exposure to the long-term push to automate and modernize factories and processing plants.
  • A large installed base, which can lead to repeat business and service revenue.
  • A long record of paying and raising dividends, which some income-focused investors value.
  • Software and services that can make results less cyclical than pure equipment sellers.

What can go wrong

  • Industrial spending is cyclical. Customers delay projects when the economy weakens or energy and commodity prices fall.
  • Competition from large automation rivals can pressure pricing and market position.
  • Acquisitions and portfolio changes carry integration risk and may not deliver the expected benefits.
  • A global footprint exposes the company to currency swings, tariffs and supply chain disruptions.
  • Dividend history does not guarantee future payments.

What to watch

  • Orders and backlog
  • Organic sales growth
  • Operating margins
  • Software and recurring revenue trends
  • Free cash flow and its use (dividends, buybacks, acquisitions)
  • Industrial activity gauges such as manufacturing surveys
  • Capital spending plans in energy and chemicals
  • Management guidance at earnings

Options income angle

Options on EMR are generally available across several expirations and are usually reasonably liquid, though not as active as the largest mega-cap names. Bid-ask spreads can be wider on less popular strikes and longer-dated contracts, so check open interest and volume first.

Implied volatility tends to rise ahead of quarterly earnings and when investors worry about the industrial cycle, energy spending, interest rates or trade policy. It often eases after results are released.

One caution for premium sellers: a stock like this can gap sharply on earnings or guidance changes. A covered call caps upside if shares jump, and a cash-secured put can leave you owning shares after a drop. Calls can also be assigned early around ex-dividend dates.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended September 30, 2026, filed November 9, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Emerson's fiscal 2026 sales rose 5 percent and earnings grew faster, led by its software and systems businesses. The company carries debt from the AspenTech purchase, tariff policy remains unsettled, and it guides to about 5 percent sales growth for fiscal 2027, assuming the Middle East conflict stays contained within the region.

How the business did

  • Net sales were $19.0 billion, up 5 percent. Underlying sales (which exclude currency, acquisitions and divestitures) rose 4 percent on 3 percent higher price and 1 percent higher volume. Underlying sales were up 9 percent in the U.S. and 1 percent internationally.
  • Earnings from continuing operations were $2,691 million, up 19 percent. Diluted earnings per share were $4.79, and adjusted earnings per share, which strips out items such as intangibles amortization and restructuring, were $6.59, up 10 percent.
  • Software & Systems sales rose 8 percent, with Test & Measurement up 17 percent. Intelligent Devices rose 4 percent and Safety & Productivity rose 3 percent. China underlying sales fell 7 percent.
  • Operating cash flow was $3,978 million and free cash flow was $3,535 million. The company paid dividends of $1,244 million, bought back $1,000 million of stock, and total debt fell to $12,175 million from $13,116 million.
  • Unusual items: tariff refunds of $121 million after the Supreme Court ruled against the IEEPA tariffs, a roughly 1 percent drag on sales from software renewal timing and the Middle East conflict, and a switch to mark-to-market pension accounting.

Risks specific to this company

  • Tariffs and trade policy: The filing says changing U.S. tariffs and retaliatory measures may have a material adverse impact. The company says it cannot be sure it can offset all of the effect.
  • Debt and funding access: Interest expense, net was $334 million, up from $237 million, because borrowing funded the AspenTech purchase. The company says it needs capital markets access to refinance maturing debt.
  • Manufacturing abroad: A majority of production facilities are outside the U.S., and emerging market sales are over one-third of total sales. War, political unrest or nationalization could disrupt shipments.
  • Narrower portfolio: After the AspenTech, National Instruments and Copeland deals, the company says it may face more volatility and be more vulnerable to changing market conditions. Integration may not deliver the expected benefits.
  • Litigation and asbestos: The company faces product liability claims including asbestos, and its reserve is based on projected claims through 2065. Management believes a material adverse impact is unlikely.
  • Artificial intelligence: Competitors may use AI faster or better, and the filing expects AI to make cyberattacks more sophisticated.

What management is watching

  • Fiscal 2027 sales are expected to be up approximately 5 percent, with underlying sales also up approximately 5 percent. Earnings per share are expected to be approximately $5.70, and adjusted earnings per share approximately $7.25.
  • Operating cash flow is expected to be $4.3 to $4.4 billion and free cash flow $3.8 to $3.9 billion, with capital spending of approximately $0.5 billion. The plan returns approximately $3.8 billion to shareholders, including approximately $2.5 billion of share repurchases and approximately $1.3 billion of dividends.
  • The Board raised the quarterly dividend to an annualized rate of $2.38 per share in November 2026.
  • Management points investors to underlying sales, adjusted EBITA (earnings before interest, taxes, intangibles amortization and certain one-time items), adjusted earnings per share and free cash flow. Adjusted EBITA was $5,054 million, a 26.6 percent margin.
  • The company expects the One Big Beautiful Bill Act to slightly benefit its tax rate beginning in fiscal 2027.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended June 30, 2026, filed August 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Emerson's third quarter of fiscal 2026 brought net sales of $4.9 billion, up 7 percent, and diluted earnings per share from continuing operations of $1.28, up 24 percent. Part of the profit gain came from $82 million of IEEPA tariff refunds, a one-time item the company excludes from its adjusted figures. Adjusted diluted earnings per share were $1.71, up 13 percent.

How the business did

  • Sales: Underlying sales, which strip out currency swings, acquisitions and divestitures, rose 6 percent on 3 percent higher volume and 3 percent higher price. For the nine months, net sales were $13.8 billion, up 5 percent. Underlying sales were up 3 percent, with volume reduced by approximately 1.5 percent from the timing of software renewals and the conflict in the Middle East.
  • Profit: Gross margin was 54.5 percent, up 1.9 percentage points, mainly because of the tariff refunds. After a February 2026 Supreme Court ruling that IEEPA does not authorize tariffs, the company filed claims and received the refunds, which were recorded in Cost of sales. Pretax earnings were $916 million, up 25 percent. Adjusted EBITA (earnings before interest, taxes, intangibles amortization and certain items) was $1,303 million, up 10 percent. Restructuring costs rose to $87 million from $37 million.
  • Segments: Software & Systems sales rose 11 percent, led by Test & Measurement, up 23 percent on semiconductor and aerospace & defense demand. Intelligent Devices sales rose 6 percent, with strength in power and LNG. Safety & Productivity sales rose 3 percent, but its earnings fell $10 million, down 10 percent, on higher restructuring costs and lower volume. Europe underlying sales were down 1 percent and China was down 3 percent.
  • Cash and capital return: For the nine months, operating cash flow from continuing operations was $2,902 million and free cash flow was $2,618 million. The company spent $898 million on share repurchases and $935 million on dividends. Net interest expense for the nine months was $258 million, up from $145 million because of debt used to fund the AspenTech acquisition.

What management is watching

  • Full-year outlook: Net sales are expected to be up approximately 5 percent, with underlying sales up approximately 3.5 percent. Earnings per share are expected to be approximately $4.89, and adjusted earnings per share approximately $6.55.
  • Cash and returns: Operating cash flow is expected to be approximately $4.1 billion and free cash flow approximately $3.6 billion, after projected capital spending of approximately $0.45 billion. The plan assumes returning approximately $2.2 billion to shareholders, through approximately $1.0 billion of share repurchases and approximately $1.2 billion of dividends.
  • Tariff refunds and taxes: The timing and amount of any further IEEPA refunds remain uncertain, so no benefit was recognized for them. The OBBBA tax law raised the effective tax rate by approximately 1 percentage point this year, and the company expects it to slightly benefit the rate beginning in fiscal 2027.
  • Measures highlighted: Management points investors to adjusted earnings per share and adjusted EBITA margin, which was 26.7 percent for the quarter.

Follow EMR in Kortex

The Kortex app shows EMR's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.